Azione COV CLEO DIAGNOSTICS LTD
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Cleo Diagnostics Ltd

Azioni

COV

AU0000288045

Tempo differito Australian S.E.
Altri mercati azionari
 04:23:51 02/07/2024 		Variaz. 5gg Var. 1 gen.
0,4 AUD +8,11% Grafico intraday di Cleo Diagnostics Ltd +31,15% +128,57%
29/05 Uno studio rileva che il test del sangue di Cleo Diagnostics ' supera i benchmark clinici MT
02/04 CLEO punta su HcFocus per l'ingresso nel mercato statunitense MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Cleo Diagnostics Secures US FDA Feedback for Ovarian Cancer Test
7,500,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 23-JUN-2024.
Study Finds Cleo Diagnostics ' Blood Test Outperforms Clinical Benchmarks
Cleo Diagnostics Taps Lindus Health to Manage US Ovarian Cancer Clinical Trials
CLEO Taps HcFocus for US Market Entry
Cleo Diagnostics Concludes Design Transfer of Ovarian Cancer Detection Test Technology
50,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 1-DEC-2023.
162,500 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 30-NOV-2023.
Cleo Diagnostics Confirms Efficacy of Ovarian Cancer Test from Validation Study; Shares Surge 21%
50,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 4-NOV-2023.
425,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 21-OCT-2023.
75,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 19-OCT-2023.
150,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 18-OCT-2023.
100,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 13-OCT-2023.
Cleo Diagnostics Advances Development of Cancer Test Kit
CLEO Diagnostics’ Chief Scientific Officer Move to Full-Time Arrangement
150,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 30-SEP-2023.
125,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 21-SEP-2023.
37,500 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 19-SEP-2023.
CLEO Diagnostics Secures US Patent for Ovarian Cancer Biomarker Testing
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione COV
  4. Notizie Cleo Diagnostics Ltd
  5. Altre lingue